This is the authors' abstract. We don't add key points for this paper.
STRUCTURED ABSTRACT INTRODUCTION Recent advances allow blood tests to detect key proteins linked to Alzheimer’s disease (AD). METHODS In this before-and-after study across three Australian Memory and Cognition Clinics, we evaluated the impact on clinicians’ diagnostic confidence and management following disclosure of routine patients’ AD probability, using predefined plasma pTau181 thresholds set at 90% sensitivity and 90% specificity for amyloid-β (Aβ) PET positivity. RESULTS 113 participants (age:71.2±8.4; MMSE:27.7±2.5) with dementia (n=17, 15.0%), mild cognitive impairment (n=48, 42.5%) and subjective cognitive decline (n=48, 42.5%) were enrolled. Blood test results were ‘probably negative’, n=81, 71.7%; indeterminate, n=24, 21.2%; ‘probably positive’, n=8, 7.1%. In 12 cases (10.6%), pTau181 changed clinician diagnosis and increased mean diagnostic confidence from low-to-moderate (61%) to moderate-to-high (80%). Aβ-PET in 40 participants showed plasma pTau181 improved diagnostic accuracy by 5%. DISCUSSION This study demonstrates the benefits of plasma pTau181 in real-world clinical practice particularly when diagnostic confidence is only low-to-moderate.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Michaelian et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: